Paroxysmal Atrial FibrillationCRY-OUT-CATNCT04344743
Balloon Cryoablation Without Contrast
A study testing Cryoballoon ablation without contrast in people with Paroxysmal Atrial Fibrillation, run by Medicover Hospital at 2 sites in Poland.
Trial summary
Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Paroxysmal Atrial Fibrillation
- What is being tested?
- Cryoballoon ablation without contrast
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 2 sitesPoland
- Study dates
- 13 Aug 2020to Jun 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with paroxysmal AF - episodes lasting up to 7 days or cardioverted before this time
- At least 4 AF attacks in the last 12 months
- Informed consent for participation in the study
- Age > 18 and < 70 years
- Left atrium diameter (PLAX) < 4,5 cm and left atrial area < = 30 cm2
- Left ventricle ejection fraction > 45%
- Four separate veins visualised in computed tomography prior to the ablation
Who cannot join
- Withdrawal of consent for the procedure
- Documented typical atrial flutter prior to the ablation
- Thrombus in left atrium
- GFR < 60 ml/min
- Pregnancy
- Common trunk of left or right pulmonary veins documented on computed tomography (preferred) or by means of other imaging methods
- Other conditions that preclude AF ablation including: infection, uncontrolled hyperthyroidism, significant anaemia and thrombocytopenia, acute cardiac / internist / surgical conditions
Trial locations and contacts
2 sites in 1 country.
Poland2 sites, 2 recruiting
- Recruiting
Medicover Hospital
Warsaw
Pawel Derejko, MD, PhD, +48603338871, pderejko@yahoo.com
Marta Sobczynska, MD, +48666308590, marta.sobczynska@medicover.pl
- Recruiting
National Institute of Cardiology
Warsaw
Michal Orczykowski, MD, PhD, +48696775533, mikeorczyk@gmail.com
About this study
Official title: Cryoballoon Ablation Without Use of Contrast Dye for the Treatment of Paroxysmal Atrial Fibrillation
Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. It is assessed by venography, performed by injecting contrast through the inner lumen of the balloon catheter after the vein is blocked with a balloon. Achieving full vein occlusion in certain situations can be challenging and may require multiple attempts, which may expose the patient to increased doses of contrast and radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary veins.
Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation.
Read more
All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation.
Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.
Read the detailed description
Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. It is assessed by venography, performed by injecting contrast through the inner lumen of the balloon catheter after the vein is blocked with a balloon. Achieving full vein occlusion in certain situations can be challenging and may require multiple attempts, which may expose the patient to increased doses of contrast and radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary veins.
Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation.
All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation.
Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.
Course of ablation. All ablations will be performed using Medtronic Arctic Front Advance catheter system as well as future generations of Medtronic cryoballoon catheter systems.
Initially the cryoenergy will be delivered without previous venography confirming full vein occlusion. Then, in case of vein isolation failure after 5 minutes of cryoenergy delivery, further attempts to isolate the vein will be preceded by venography.
Statistical analysis. The assumed sample size (N = 50 patients/ 200 veins) will allow to estimate the number and percentage of pulmonary veins that will be isolated without the use of contrast.
The statistical analysis will use standard descriptive statistics tools: frequency tables for categorical variables; extreme values, mean value and standard deviation for normal distributed variables; and extreme values and quartiles for non-normal distributed variables.
Parameters assessed during the procedure:
Concerning a single energy cryoapplication
- Possibility of registration (occurrence vs. non-occurrence) of pulmonary vein potentials before the cryoapplication, and after the occlusion of the vein by the balloon.
- Time to vein isolation
- Cryoenergy application time / freezing time
- The minimum temperature obtained during cryoapplication
- Time to obtain temperature - 30 ° C and - 40 ° C
- Temperature after 30, 60 and 90 seconds from the beginning of cryoenergy application
- Cryoballoon heating time from -30 C to +15 C Concerning the isolation of a single vein
- Total time to complete isolation of a vein
- The number of cryoenergy applications
- Total time of cryoenergy application per vein Concerning the entire procedure:
- Total cryoenergy application time per procedure / patient
- The total amount of contrast
- Radiation dose
- Time of radiation
- Left atrial dwelling time
- Duration of the procedure (from puncture of the vein to sheaths removal)
Termination of cryoenergy delivery:
- If temperature does not reach - 30 ° C after 60 seconds of cryoenergy application (inefficient application).
- If vein isolation does not occur after 90 seconds of cryoenergy application (inefficient application).
- If temperature after 30 seconds of cryoapplication falls lower than - 50° C (unsafe application).
- When temperature reaches - 55° C (unsafe application).
- If phrenic nerve injury occurs or if symptoms suggesting its imminent occurrence are noticed (unsafe application).
- If the operator considers that the application is ineffective or performed too distally (inefficient or unsafe application).
Effective cryoenergy applications will be terminated 120 seconds after vein isolation.
Veins with no recordable pulmonary vein potentials - The above-mentioned veins will be isolated - 1 application 240 seconds. Applications will be considered effective if the minimum temperature achieved will be less than 35C and the stimulation performed from the vein after application will be ineffective.
Supplemental cryoapplications. Supplemental cryoenergy applications will not be delivered after successful isolation of the vein
Vein isolation assessment. Pulmonary vein isolation will be assessed by demonstrating entrance and exit block
Phrenic nerve function monitoring. In order to prevent PN injury/ palsy the balloon will be inflated outside PV ostia and maintained as antrally as possible during vein isolation. For phrenic nerve function monitoring pacing of the nerve during right pulmonary vein isolation will be performed. Additionally, intermittent fluoroscopy during pacing will be used for monitoring diaphragmatic motion. The ablation will be stopped at the first sign of imminent phrenic nerve injury.
Complications assessed. Transient phrenic nerve injury or palsy (resolving until discharge after index procedure) is considered a minor complication. Death, stroke, tamponade, arteriovenous fistula or pseudoaneurysm, persistent (resolving during follow up) or permanent (if not resolved at end of follow up, but >12 months) phrenic nerve palsy, bleeding with a decrease in haemoglobin of at least 2 g / dl or any other state requiring prolongation of hospitalization are considered major complications.
The duration of the project and follow-up. The study is expected to last two years. Approximately 50 patients will be enrolled, with one year follow-up. All patients will have follow-up visits in an out-patient clinic at least 3 and 12 months post PVI. Additionally at 6 weeks, 6 and 9 months post ablation telephone follow-up will be conducted by the study coordinator using standardized questionnaire.
- Conditions
- Paroxysmal Atrial Fibrillation
- Being tested
- Cryoballoon ablation without contrast
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cryoballoon ablation without contrastDevice
Cryoballoon ablation without contrast
| Study group | Role | What they receive |
|---|---|---|
| Cryoballoon ablation without contrast | Experimental | Cryoballoon ablation without contrast Receives: Device: Cryoballoon ablation without contrast |
What is being measured
The primary outcome is the main question the study is designed to answer.
Isolation of a pulmonary vein without the use of contrast and within the scheduled timeframe
Acute result will be assessed. Vein isolation assessment will be done using a diagnostic circular catheter (Achieve, Medtronic), by demonstrating entrance and exit block
Measured: Through study completion, an average of 2 years
Secondary outcomes (7)
Percentage of patients in whom isolation of all pulmonary veins will be achieved without the use of contrast
Measured: Through study completion, an average of 2 years
Percentage of patients with stable sinus rhythm, without atrial fibrillation episodes during follow-up
Measured: During one year follow-up
The amount of contrast dye used
Measured: Through study completion, an average of 2 years
X-ray time exposure
Measured: Through study completion, an average of 2 years
Radiation dose
Measured: Through study completion, an average of 2 years
Left atrial dwelling time
Measured: Through study completion, an average of 2 years
Number of complications assessed
Measured: Through study completion, an average of 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2020
- Study start13 Aug 2020
- Primary completionAug 2021 (estimated)
- Study completionJun 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Paroxysmal Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medicover Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Cardiology, Warsaw, Poland
- Responsible party
- Principal investigator, Pawel Derejko, Medicover Hospital
- Investigators
- Pawel Derejko, MD, PhD, Principal investigator, Medicover Hospital, Warsaw, Poland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04344743
- Sponsor's protocol ID
- 1_2020
- Acronym
- CRY-OUT-CAT
- Status last verified
- Sep 2020
- First submitted
- 5 Apr 2020
- Last updated
- 9 Sep 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: Individual participant data that underlie the results reported in this article, after deidentification (text, tables,figures, and appendices).
Publications
Derejko P, Kusnierz J, Bardyszewski A, Orczykowski M, Dzwonkowska D, Polanska-Skrzypczyk M, Szumowski LJ. Cryoballoon ablation without use of contrast for the treatment of paroxysmal atrial fibrillation. Cardiol J. 2024;31(5):665-674. doi: 10.5603/cj.95969. Epub 2024 Jan 30.
PubMed 38287689
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cryoballoon Ablation Without Use of Contrast Dye for the Treatment of Paroxysmal Atrial Fibrillation
- ClinicalTrials.gov ID
- NCT04344743
- Acronym / sponsor ID
- CRY-OUT-CAT / 1_2020
- Conditions
- Paroxysmal Atrial Fibrillation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Medicover HospitalUniversity, hospital or other
- Collaborators
- National Institute of Cardiology, Warsaw, Poland
- Study start
- 13 Aug 2020 (actual)
- Primary completion
- Aug 2021 (estimated)
- Study completion
- Jun 2022 (estimated)
- First posted
- 14 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. It is assessed by venography, performed by injecting contrast through the inner lumen of the balloon catheter after the vein is blocked with a balloon. Achieving full vein occlusion in certain situations can be challenging and may require multiple attempts, which may expose the patient to increased doses of contrast and radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary veins.
Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation.
All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation.
Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.
Detailed description
Pulmonary vein isolation using cryoballoon ablation is well established method for the treatment of atrial fibrillation. As a rule, cryoenergy delivery is preceded by documenting the full vein occlusion. It is assessed by venography, performed by injecting contrast through the inner lumen of the balloon catheter after the vein is blocked with a balloon. Achieving full vein occlusion in certain situations can be challenging and may require multiple attempts, which may expose the patient to increased doses of contrast and radiation.. At the same time, the purpose of ablation is an electrical isolation of pulmonary veins.
Experts postulate ablation in the antrum and the so-called "proximal-seal technique", which in some cases may require to start cryoapplication before the vein is fully sealed. This approach minimizes the risk of the pulmonary vein stenosis, damage to structures immediately adjacent to the atrium and phrenic nerve palsy. In addition, in many cases the displacement of the balloon after several dozen seconds of cryoapplication, usually by pulling it, causes full sealing of the vein, contributes to further lowering the temperature and leads to full electrical isolation of the vein, which is the aims of ablation.
All the above-mentioned facts indicate that demonstrating full vein occlusion using angiography before the initiation of cryoenergy application is of limited value. Moreover, there are a number of parameters related to cryoballoon ablation that indicate acute and long term vein isolation.
Taking into account the arguments presented above, it seems that it is possible to perform an effective and safe isolation of the pulmonary veins using the cryoballoon ablation technique without confirmation by venography that PV is occluded. Along with dissemination of the method, such attempts are and will be made by some operators. Therefore, a systematic approach to this issue is important. It should define the conditions that should be met in order for the procedure in the proposed modification to be implemented effectively and safely. In addition, a protocol of ablation for this modification is required.
Course of ablation. All ablations will be performed using Medtronic Arctic Front Advance catheter system as well as future generations of Medtronic cryoballoon catheter systems.
Initially the cryoenergy will be delivered without previous venography confirming full vein occlusion. Then, in case of vein isolation failure after 5 minutes of cryoenergy delivery, further attempts to isolate the vein will be preceded by venography.
Statistical analysis. The assumed sample size (N = 50 patients/ 200 veins) will allow to estimate the number and percentage of pulmonary veins that will be isolated without the use of contrast.
The statistical analysis will use standard descriptive statistics tools: frequency tables for categorical variables; extreme values, mean value and standard deviation for normal distributed variables; and extreme values and quartiles for non-normal distributed variables.
Parameters assessed during the procedure:
Concerning a single energy cryoapplication
- Possibility of registration (occurrence vs. non-occurrence) of pulmonary vein potentials before the cryoapplication, and after the occlusion of the vein by the balloon.
- Time to vein isolation
- Cryoenergy application time / freezing time
- The minimum temperature obtained during cryoapplication
- Time to obtain temperature - 30 ° C and - 40 ° C
- Temperature after 30, 60 and 90 seconds from the beginning of cryoenergy application
- Cryoballoon heating time from -30 C to +15 C Concerning the isolation of a single vein
- Total time to complete isolation of a vein
- The number of cryoenergy applications
- Total time of cryoenergy application per vein Concerning the entire procedure:
- Total cryoenergy application time per procedure / patient
- The total amount of contrast
- Radiation dose
- Time of radiation
- Left atrial dwelling time
- Duration of the procedure (from puncture of the vein to sheaths removal)
Termination of cryoenergy delivery:
- If temperature does not reach - 30 ° C after 60 seconds of cryoenergy application (inefficient application).
- If vein isolation does not occur after 90 seconds of cryoenergy application (inefficient application).
- If temperature after 30 seconds of cryoapplication falls lower than - 50° C (unsafe application).
- When temperature reaches - 55° C (unsafe application).
- If phrenic nerve injury occurs or if symptoms suggesting its imminent occurrence are noticed (unsafe application).
- If the operator considers that the application is ineffective or performed too distally (inefficient or unsafe application).
Effective cryoenergy applications will be terminated 120 seconds after vein isolation.
Veins with no recordable pulmonary vein potentials - The above-mentioned veins will be isolated - 1 application 240 seconds. Applications will be considered effective if the minimum temperature achieved will be less than 35C and the stimulation performed from the vein after application will be ineffective.
Supplemental cryoapplications. Supplemental cryoenergy applications will not be delivered after successful isolation of the vein
Vein isolation assessment. Pulmonary vein isolation will be assessed by demonstrating entrance and exit block
Phrenic nerve function monitoring. In order to prevent PN injury/ palsy the balloon will be inflated outside PV ostia and maintained as antrally as possible during vein isolation. For phrenic nerve function monitoring pacing of the nerve during right pulmonary vein isolation will be performed. Additionally, intermittent fluoroscopy during pacing will be used for monitoring diaphragmatic motion. The ablation will be stopped at the first sign of imminent phrenic nerve injury.
Complications assessed. Transient phrenic nerve injury or palsy (resolving until discharge after index procedure) is considered a minor complication. Death, stroke, tamponade, arteriovenous fistula or pseudoaneurysm, persistent (resolving during follow up) or permanent (if not resolved at end of follow up, but >12 months) phrenic nerve palsy, bleeding with a decrease in haemoglobin of at least 2 g / dl or any other state requiring prolongation of hospitalization are considered major complications.
The duration of the project and follow-up. The study is expected to last two years. Approximately 50 patients will be enrolled, with one year follow-up. All patients will have follow-up visits in an out-patient clinic at least 3 and 12 months post PVI. Additionally at 6 weeks, 6 and 9 months post ablation telephone follow-up will be conducted by the study coordinator using standardized questionnaire.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cryoballoon ablation without contrast | Experimental | Device: Cryoballoon ablation without contrastCryoballoon ablation without contrast |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients with paroxysmal AF - episodes lasting up to 7 days or cardioverted before this time
- At least 4 AF attacks in the last 12 months
- Informed consent for participation in the study
- Age > 18 and < 70 years
- Left atrium diameter (PLAX) < 4,5 cm and left atrial area < = 30 cm2
Key exclusion criteria (7 listed)
- Withdrawal of consent for the procedure
- Documented typical atrial flutter prior to the ablation
- Thrombus in left atrium
- GFR < 60 ml/min
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cryoballoon ablation without contrastCryoballoon ablation without contrast | Device | Cryoballoon ablation without contrast |
Primary outcome
Isolation of a pulmonary vein without the use of contrast and within the scheduled timeframe
Time frame: Through study completion, an average of 2 years
Acute result will be assessed. Vein isolation assessment will be done using a diagnostic circular catheter (Achieve, Medtronic), by demonstrating entrance and exit block
7 secondary outcomes
Percentage of patients in whom isolation of all pulmonary veins will be achieved without the use of contrast
Time frame: Through study completion, an average of 2 years
Percentage of patients with stable sinus rhythm, without atrial fibrillation episodes during follow-up
Time frame: During one year follow-up
The amount of contrast dye used
Time frame: Through study completion, an average of 2 years
X-ray time exposure
Time frame: Through study completion, an average of 2 years
Radiation dose
Time frame: Through study completion, an average of 2 years
Left atrial dwelling time
Time frame: Through study completion, an average of 2 years
Number of complications assessed
Time frame: Through study completion, an average of 2 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2020.
- Derived from this study: PubMed 38287689Derejko P, Kusnierz J, Bardyszewski A, Orczykowski M, Dzwonkowska D, Polanska-Skrzypczyk M, Szumowski LJ. Cryoballoon ablation without use of contrast for the treatment of paroxysmal atrial fibrillation. Cardiol J. 2024;31(5):665-674. doi: 10.5603/cj.95969. Epub 2024 Jan 30.
- Individual participant dataSharing planned: Yes. Individual participant data that underlie the results reported in this article, after deidentification (text, tables,figures, and appendices).
Related trials for Paroxysmal Atrial Fibrillation
Active, not recruiting
A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF
Atrial Fibrillation
Recruiting
A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation
RecruitingObservational study
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
Atrial Fibrillation
Active, not recruitingObservational study
THERMOCOOL SMARTTOUCH®SF Catheters With Ablation Index Study
Paroxysmal Atrial Fibrillation
Not yet recruitingObservational study
Catheter Ablation Using a Novel Navigation and Imaging System
Paroxysmal Atrial Fibrillation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pawel Derejko, MD, PhD principal investigator
Medicover Hospital, Warsaw, Poland
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cryoballoon ablation without contrast in people with Paroxysmal Atrial Fibrillation, run by Medicover Hospital at 2 sites in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Pawel Derejko, MD, PhD (+48603338871, pawel.derejko@medicover.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Isolation of a pulmonary vein without the use of contrast and within the scheduled timeframe (time frame: Through study completion, an average of 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04344743, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2020.